Medicines Australia is on the lookout for a new CEO following the confirmed departure of Milton Catelin.
Mr Catelin will depart the association in mid-April following an 18-month tenure as CEO of the representative association of the research-based pharmaceutical industry. He is returning to the UK where his family is based.
During his time in the role, the association negotiated a strategic agreement with government and $1.8 billion in new savings. It is currently locked in negotiation with government over further reforms.
Speculation regarding Mr Catelin's tenure emerged just months after he began in the role.
PharmaDispatch wrote in July last year he was unlikely to remain in the job for a long period.
At the time, Medicines Australia told member companies he remained "committed" to the association.
Medicines Australia will now start a recrutiment process for a new CEO.
Medicines Australia Chair Wes Cook thanked Mr Catelin, stating, “On behalf of the Board and our members I would like to thank Milton Catelin for his contribution to the innovative medicines industry.
"Milton is leaving Medicines Australia following a period of significant transformation and growth for our sector,” he said.